After two rounds of mixed data, Eli Lilly impresses analysts with new Covid-19 antibody results. And execs want an EUA now
Eli Lilly has more data from their Covid-19 neutralizing antibodies — data, they say, should warrant an FDA OK.
The Big Pharma said Wednesday that a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
